Citigroup
APGE icon

Citigroup’s Apogee Therapeutics APGE Stock Holding History

Citigroup’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.18M Buy
13,988
+5,106
+57% +$371K ﹤0.01% 3007
2025
Q4 		$670K Buy
8,882
+2,378
+37% +$150K ﹤0.01% 3398
2025
Q3 		$258K Sell
6,504
-16,424
-72% -$627K ﹤0.01% 3885
2025
Q2 		$996K Sell
22,928
-38,434
-63% -$1.46M ﹤0.01% 3197
2025
Q1 		$2.29M Buy
61,362
+5,260
+9% +$203K ﹤0.01% 2573
2024
Q4 		$2.54M Buy
56,102
+27,968
+99% +$1.43M ﹤0.01% 2614
2024
Q3 		$1.65M Buy
28,134
+10,023
+55% +$480K ﹤0.01% 2830
2024
Q2 		$713K Sell
18,111
-74,995
-81% -$3.64M ﹤0.01% 3151
2024
Q1 		$6.19M Buy
93,106
+89,337
+2,370% +$3.9M ﹤0.01% 1559
2023
Q4 		$105K Buy
+3,769
New +$75.6K ﹤0.01% 4184

Other funds holding APGE

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Citigroup's APGE Position: Q1 2026 in Review

Citigroup increased its Apogee Therapeutics (APGE) stake by 57% in Q1 2026, buying an estimated $371K and bringing the position to 13,988 shares worth $1.18M. The position accounts for ﹤0.01% of the portfolio, ranked #3007.

Citigroup first reported a position in APGE in Q4 2023 and has held it in 10 quarters since. The position peaked at $6.19M in Q1 2024. 224 funds tracked by Wall St. Rank hold APGE as of Q1 2026.

  • Citigroup held 13,988 shares of Apogee Therapeutics worth $1.18M as of Q1 2026.
  • Citigroup bought 5,106 Apogee Therapeutics shares in Q1 2026, an estimated $371K.
  • Apogee Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3007 holding.
  • Citigroup first reported a position in Apogee Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • Citigroup's Apogee Therapeutics position peaked at $6.19M in Q1 2024.
  • 224 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.